Rhythm Pharmaceuticals Inc (RYTM)
37.99
-1.18
(-3.01%)
USD |
NASDAQ |
May 17, 16:00
37.99
0.00 (0.00%)
After-Hours: 20:00
Rhythm Pharmaceuticals Revenue (Quarterly): 25.97M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 25.97M |
| December 31, 2023 | 24.23M |
| September 30, 2023 | 22.50M |
| June 30, 2023 | 19.22M |
| March 31, 2023 | 11.47M |
| December 31, 2022 | 8.79M |
| September 30, 2022 | 4.284M |
| Date | Value |
|---|---|
| June 30, 2022 | 9.066M |
| March 31, 2022 | 1.498M |
| December 31, 2021 | 1.817M |
| September 30, 2021 | 1.028M |
| June 30, 2021 | 0.274M |
| March 31, 2021 | 0.035M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.035M
Minimum
Mar 2021
25.97M
Maximum
Mar 2024
10.01M
Average
8.79M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 14.88B |
| Amicus Therapeutics Inc | 110.40M |
| Insmed Inc | 75.50M |
| Altimmune Inc | 0.005M |
| Regeneron Pharmaceuticals Inc | 3.145B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -141.37M |
| Total Expenses (Quarterly) | 165.85M |
| EPS Diluted (Quarterly) | -2.35 |
| Enterprise Value | 2.113B |
| Gross Profit Margin (Quarterly) | 89.19% |
| Profit Margin (Quarterly) | -544.4% |
| Earnings Yield | -12.20% |
| Normalized Earnings Yield | -12.20 |